Actively Recruiting
Ablative Radiation Therapy With High Dose Geometric Boost for Locally Advanced Pancreatic Cancer Patients After Response to Standard Chemotherapy
Led by University Health Network, Toronto · Updated on 2026-04-16
43
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of high-dose radiation therapy in patients with locally advanced pancreatic cancer who have responded to initial chemotherapy. This Phase II clinical trial aims to determine whether this radiation treatment can improve outcomes, quality of life, or overall survival rates for these patients. The study is sponsored by the University Health Network, Toronto, and focuses on patients whose cancer has remained stable or decreased in size after chemotherapy. Participants will receive high-dose radiation therapy delivered in fractions over set periods, such as 50 Gray over 5 sessions every other day in 2 weeks, 67.5 Gray over 15 sessions daily in 3 weeks, or 75 Gray over 25 sessions daily in 5 weeks. The specific radiation dose and schedule will be determined by the radiation oncologist based on each participant's condition. An optional tumor biopsy may be performed before treatment. During the study, participants will complete quality of life questionnaires and donate blood samples for research. Researchers will monitor overall survival over 5 years as the primary outcome. Participants must be able to give informed consent and will be followed closely to assess treatment effects and safety. The study will begin in March 2025 and continue through April 2030.
CONDITIONS
Brief Title
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a histological or cytological diagnosis of locally advanced pancreatic cancer (LAPC)
- Pancreatic tumor less than 8.0 cm in greatest axial dimension at treatment planning, meeting radiation tissue constraints
- Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less (Karnofsky score 70% or higher)
- Life expectancy greater than 6 months as judged by the investigator
- Completed at least 16 weeks of first-line chemotherapy for this cancer without progression
- At least 2 weeks since last chemotherapy before starting trial therapy
- Able to understand and willing to sign informed consent
- Women must not be pregnant or breastfeeding and must have a negative pregnancy test within 4 weeks before registration
- Breastfeeding women must stop breastfeeding before registration
You will not qualify if you...
- Metastatic disease at registration
- Age under 18 years
- Prior systemic treatment in metastatic setting
- Prior radiotherapy to upper abdomen overlapping current radiation area
- Currently receiving any anti-cancer treatment including chemotherapy
- Uncontrolled illness such as active infection, heart failure, unstable angina, arrhythmia, or psychiatric/social issues limiting compliance
- Pregnant or breastfeeding women
- Other conditions contraindicating safe participation as judged by investigator
- History of other malignancy unless disease-free for at least 2 years and low risk of recurrence; exceptions include cervical cancer in situ and certain skin cancers diagnosed in past 5 years
- Diseases preventing high dose radiation such as scleroderma or ulcers within treatment area
- Contraindications for MRI including pacemaker, metallic foreign bodies, severe claustrophobia, prior anaphylaxis to gadolinium, or severe kidney disease (glomerular filtration rate below 30 mL/min/1.73m2) or acute kidney disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 to 5 weeks depending on radiation schedule
Participants receive high dose radiation therapy delivered in fractions over a set period to target and treat the tumor. The radiation dose and schedule are determined by the radiation oncologist and may be administered every other day over 2 weeks or once daily over 3 to 5 weeks.
Daily or every other day visits during treatment (5 to 25 sessions)
Trial Site Locations
Total: 2 locations
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
2
McGill University Health Centre
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
Research Team
A
Anna Dodd
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here